ArticleCureus2025
Atypical Presentation in X-linked Immunodeficiency With Magnesium Defect, Epstein-Barr Virus (EBV) Infection, and Neoplasia (XMEN) Disease: A Case Report and Review of Emerging Therapies.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia (XMEN) is a rare primary immunodeficiency caused by MAGT1 mutations. These mutations impair N-linked glycosylation and magnesium-dependent signaling in T cells, disrupting immune surveillance. XMEN typically presents with chronic Epstein-Barr virus (EBV) viremia, lymphoproliferative disease, and viral infections, although phenotypic variability is increasingly recognized. A seven-year-old male presented at age five with bilateral conjunctival hemorrhages and petechiae and was found to have severe thrombocytopenia (platelet count: 4,000/µL). Initial treatment for presumed idiopathic thrombocytopenia (ITP) with idiopathic thrombocytopenic purpura (IVIG) and corticosteroids yielded minimal improvement. Bone marrow biopsy excluded malignancy, and he was maintained on romiplostim with variable platelet recovery. Two years later, he was evaluated by genetics due to persistent ITP, steroid side effects, and disseminated molluscum contagiosum. Genetic testing revealed a pathogenic hemizygous deletion of exons 2-10 in MAGT1, confirmed by chromosomal microarray. This deletion is consistent with XMEN disease. Family testing showed no mutation in his two full brothers, suggesting a de novo variant. Despite low platelet counts and elevated liver enzymes, he remained free of systemic infections and EBV-related complications. Magnesium supplementation resulted in moderate improvement of molluscum contagiosum lesions, but thrombocytopenia persisted. This case illustrates an atypical presentation of XMEN disease, with isolated thrombocytopenia and cutaneous viral infection in the absence of EBV viremia or lymphoproliferative disease. It supports a broader clinical spectrum for XMEN and underscores the need for continued research into genotype-phenotype correlations and targeted therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.